Sirius Therapeutics key facts
as of Oct 2026- Developer and researcher of novel RNAi therapies intended to treat chronic diseases.
- Sirius Therapeutics is valued at approximately $252.5M as of Oct 2026 (last reported valuation).
- It has raised $214.0M; the latest was IPO in Sep 2025.
- Notable investors include OrbiMed, Hankang Capital, Image Frame Investment, BioTrack Capital, CRISPR Therapeutics — 7 tracked in total.
- Status: In IPO Registration.
Sirius Therapeutics's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Sirius Therapeutics: the Monday email on marks, rounds and moves
Sirius Therapeutics funding rounds
No funding rounds for Sirius Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Sirius Therapeutics
7Sirius Therapeutics valuation
Sirius Therapeutics's last reported valuation was $253 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Sirius Therapeutics investors
7 investors are on record for Sirius Therapeutics, including OrbiMed, Hankang Capital, Image Frame Investment and BioTrack Capital.
About Sirius Therapeutics
Developer and researcher of novel RNAi therapies intended to treat chronic diseases. The company provides research and development of RNAi technology and therapeutics for the management of chronic diseases, providing solutions for physicians and patients to manage cardiovascular diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Employees
- 36
- Website
- siriusrna.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.